B&R Clinical Sp. z o.o.
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At B&R Clinical in Kielce, the respiratory research portfolio focuses on chronic obstructive pulmonary disease and related lung health concerns. The trials are designed to assess whether new treatment approaches can better control symptoms, reduce flare-ups, and improve longer-term cardiopulmonary outcomes.
- Studying COPD to improve control of severe cardiopulmonary outcomes and overall disease burden
- Evaluating new therapies aimed at lowering moderate to severe exacerbations in people with advanced respiratory disease
- Comparing treatment options to understand which approaches may offer better effectiveness for patients with persistent breathing problems
This work reflects a strong interest in respiratory medicine, with a clear focus on testing treatments that may help people living with chronic and difficult-to-manage lung disease.
Otorhinolaryngologic Diseases
The site also supports research in ear, nose, and throat disorders, especially chronic rhinosinusitis with nasal polyps. These studies aim to better understand symptom relief, nasal congestion, and polyp reduction while also capturing how patients experience treatment in everyday life.
- Investigating CRSwNP to reduce nasal congestion and improve endoscopic nasal polyp findings
- Exploring patient-reported experiences to learn how treatment affects symptoms, comfort, and satisfaction
- Assessing whether new biologic therapies can offer meaningful benefit beyond standard nasal corticosteroid care
This area highlights a patient-centered approach to ENT research, combining clinical outcomes with participant experience to better inform future care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in B&R Clinical Sp. z o.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Lebrikizumab in Chronic Rhinosinusitis with Nasal Polyps on Intranasal Corticosteroids: A Phase 3 Randomized Controlled Trial | Eli Lilly & Co. | Phase III | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 2 | Unknown | 2024-02-12 | 2024-07-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.